. Author manuscript; available in PMC: 2023 Jun 10.

Published in final edited form as: Clin Genitourin Cancer. 2022 Jun 5;20(5):e440–e452. doi: 10.1016/j.clgc.2022.06.001

Table 3.

Liver and Bone Metastatic Disease Model.

	Metastatic Sites	ORR	aOR	PFS	aHR	OS	aHR
1st line ICI
	No liver-bone	33 (28–39)	Reference	9 (6–13)	Reference	17 (13–21)	Reference
	Bone - only	21 (14–32)	0.48 (0.25–0.91) ^a b	3 (2–6)	1.65 (1.19–2.30) ^a c	7 (4–11)	1.60 (1.13–2.25) ^a d
	Liver - only	15 (7–28)	0.31 (0.13–0.75) ^a b	2 (2–3)	2.54 (1.77–3.66) ^a c	5 (3–7)	2.35 (1.66–3.34) ^a d
	Liver & bone	4 (1–22)	0.08 (0.01–0.06) ^a b	2 (1–3)	3.23 (1.96–5.32) ^a c	2 (1–5)	3.66 (2.31–5.79) ^a d
2nd line ICI or greater
	No liver-bone	28 (23–35)	Reference	6 (5–8)	Reference	12 (9–15)	Reference
	Bone - only	12 (7–20)	0.29 (0.13–0.67) ^a e	4 (3–5)	1.71 (1.28–2.28) ^a f	7 (5–9)	1.76 (1.32–2.35) ^a f
	Liver - only	25 (16–37)	0.70 (0.34–1.45) ^e	3 (2–6)	1.62 (1.09–2.41) ^a f	7 (4–11)	1.56 (1.04–2.34) ^a f
	Liver & Bone	11 (4–27)	0.45 (0.15–1.39) ^e	2 (2–3)	2.32 (1.34–4.03) ^a f	3 (2–5)	2.53 (1.47–4.38) ^a f

P < .05.

adjusted for cystectomy, site of primary (upper vs lower) and albumin at ICI initiation.

adjusted for albumin at ICI initiation.

adjusted for ECOG PS at ICI initiation.

adjusted for cystectomy, hemoglobin, albumin and NLR at ICI initiation.

adjusted for cystectomy and NLR at ICI initiation.